CASE STUDY
Cutting Startup from ~28 Weeks to 15–16 Weeks While Reducing Escalation Response by 40%
Setting the Context
A mid-size biotech preparing a first-in-human Phase 1 study faced extending startup timelines despite finalized protocols and selected sites. With investor milestones tied to progress, delays in IRB preparation, revision cycles, and submission tracking created downstream enrollment risk.
CASE STUDY
Cutting Startup from ~28 Weeks to 15–16 Weeks While Reducing Escalation Response by 40%
Setting the Context
A mid-size biotech preparing a first-in-human Phase 1 study faced extending startup timelines despite finalized protocols and selected sites. With investor milestones tied to progress, delays in IRB preparation, revision cycles, and submission tracking created downstream enrollment risk.
.jpeg)
.gif)
Challenges
Delayed status visibility across sites
Manual IRB drafting and revision cycles
Escalations triggered after timelines slipped
Fragmented tracking via spreadsheets and email
Limited forward visibility into activation bottlenecks
Operational Solution
Protocol-aware IRB package generation to reduce drafting time
Automated submission tracking across sites
AI-driven milestone monitoring with early deviation flags
Continuous review of approval velocity instead of periodic updates
Unified leadership dashboard for structured oversight
Measured Impact
After deploying AI-enabled CRO delivery services
~28 weeks to 15–16 weeks
Startup timeline reduced from
~20–25%
IRB revision cycles reduced by
1–2 weeks to 2–3 days
Delay detection improved from
~40%
Escalation response time reduced by
Enrollment Performance: Before Agentic AI vs After Agentic AI
Metric
Startup duration
IRB revision cycles
Delay detection
Escalation response
Forecast confidence
Before Deployment
~28 weeks
Multiple iterations
1–2-week lag
3–5 days
Moderate
After Deployment
~15–16 weeks
Reduced by ~20–25%
2-3 days
1–2 days
High and stable